Synergistic effects of cryoablation and GM-CSF in colorectal liver metastases management in tumor-bearing mice

Document Type : Original Article

Authors

1 Department of Colorectal Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China

2 National Clinical Research Center for Cancer, Tianjin, 300060, China

3 Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China

4 Tianjin’s Clinical Research Center for Cancer, Tianjin, 300060, China

Abstract

Objective(s): The use of cryoablation for colorectal liver metastases (CLM) remains limited and controversial. This study aimed to investigate the antitumor immune response following cryoablation combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) treatment in a CLM mouse model.
Materials and Methods: A CLM mouse model was established using BALB/c mice. The tumor-bearing mice were randomly divided into Control group, GM-CSF group, cryoablation group, and cryoablation + GM-CSF group. Tumor size, survival time, dendritic cells (DCs) count, serum cytokine levels (IL-4, IFN-γ), and the Th1/Th2 ratio (IFN-γ/IL-4) were compared among the four groups.
Results: The combination of cryoablation and GM-CSF demonstrated synergistic effects, resulting in the smallest tumor lesion, longest mean survival time, and highest DC count on day 21 post-treatment compared to other groups. Both cryoablation alone and combined with GM-CSF significantly increased serum IFN-γ levels and suppressed IL-4 levels on day 21 compared to pre-treatment levels (P<0.05). Notably, the combination of cryoablation and GM-CSF significantly elevated the Th1/Th2 ratio (P<0.05).
Conclusion: Combining cryoablation with GM-CSF treatment holds promise for CLM management. It exhibits increased DC infiltration within the tumor microenvironment, enhanced immune responses, and prolonged survival in tumor-bearing mice.

Keywords

Main Subjects

References

1. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl) 2021; 134:783-791.
2. Qu R, Ma Y, Zhang Z, Fu W. Increasing burden of colorectal cancer in China. Lancet Gastroenterol Hepatol 2022; 7:700.
3. Kow AWC. Hepatic metastasis from colorectal cancer. J Gastrointest Oncol 2019; 10:1274-1298.
4. Garcia-Botella A, Sáez-Carlin P, Méndez R, Martin MP, Ortega L, Méndez JV, et al. CD133 + cell infusion in patients with colorectal liver metastases going to be submitted to a major liver resection (CELLCOL): A randomized open-label clinical trial. Surg Oncol 2020; 33:224-230.
5. Ke S, Zhan S, Zhu H, Yan D. Topics related to neoadjuvant chemotherapy for resectable liver metastases from colorectal cancer. J buon 2018; 23:296-301.
6. Carrato A. Local treatments in the unresectable patient with colorectal cancer metastasis: A review from the point of view of the medical oncologist. Cancers (Basel) 2021; 13: 5938.
7. Ng KM, Chua TC, Saxena A, Zhao J, Chu F, Morris DL. Two decades of experience with hepatic cryotherapy for advanced colorectal metastases. Ann Surg Oncol 2012; 19:1276-1283.
8. Littrup PJ, Aoun HD, Adam B, Krycia M, Prus M, Shields A. Percutaneous cryoablation of hepatic tumors: Long-term experience of a large U.S. series. Abdom Radiol (NY) 2016; 41:767-780.
9. Seifert JK, Morris DL. World survey on the complications of hepatic and prostate cryotherapy. World J Surg 1999; 23:109-114.
10. Pathak S, Jones R, Tang JM, Parmar C, Fenwick S, Malik H, et al. Ablative therapies for colorectal liver metastases: A systematic review. Colorectal Dis 2011; 13:e252-265.
11. Sabel MS, Arora A, Su G, Chang AE. Adoptive immunotherapy of breast cancer with lymph node cells primed by cryoablation of the primary tumor. Cryobiology 2006; 53:360-366.
12. Sabel MS. Cryo-immunology: A review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Cryobiology 2009; 58:1-11.
13. Frühling P, Nilsson A, Duraj F, Haglund U, Norén A. Single-center nonrandomized clinical trial to assess the safety and efficacy of irreversible electroporation (IRE) ablation of liver tumors in humans: Short to mid-term results. Eur J Surg Oncol 2017; 43:751-757.
14. Chu KF, Dupuy DE. Thermal ablation of tumours: Biological mechanisms and advances in therapy. Nat Rev Cancer 2014; 14:199-208.
15. Lee KMC, Achuthan AA, Hamilton JA. GM-CSF: A promising target in inflammation and autoimmunity. Immunotargets Ther 2020; 9:225-240.
16. Achuthan AA, Lee KMC, Hamilton JA. Targeting GM-CSF in inflammatory and autoimmune disorders. Semin Immunol 2021; 54:101523.
17. Hong I-S. Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types. Exp Mol Med 2016; 48:e242-e242.
18. Xiong FQ, Zhang W, Zheng C, Li Y, Gong X, Zhang Y, et al. Gemcitabine-loaded synthetic high-density lipoprotein preferentially eradicates hepatic monocyte-derived macrophages in mouse liver with colorectal cancer metastases. Acta Pharmacol Sin 2023; 44:2331-2341.
19. Dai S, Wei D, Wu Z, Zhou X, Wei X, Huang H, et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther 2008; 16:782-790.
20. Potmesil M, Vardeman D, Kozielski AJ, Mendoza J, Stehlin JS, Giovanella BC. Growth inhibition of human cancer metastases by camptothecins in newly developed xenograft models. Cancer Res 1995; 55:5637-5641.
21. Ead JK, Armstrong DG. Granulocyte-macrophage colony-stimulating factor: Conductor of the wound healing orchestra? Int Wound J 2023;20:1229-1234.
22. Seifert JK, Junginger T, Morris DL. A collective review of the world literature on hepatic cryotherapy. J R Coll Surg Edinb 1998; 43:141-154.
23. Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 2002; 60:3-11.
24. Si T, Guo Z, Hao X. Combined cryoablation and GM-CSF treatment for metastatic hormone refractory prostate cancer. J Immunother 2009; 32:86-91.
25. Barqawi AB, Rodrigues Pessoa R, Crawford ED, Al-Musawi M, MacDermott T, O’Donell C, et al. Boosting immune response with GM-CSF optimizes primary cryotherapy outcomes in the treatment of prostate cancer: A prospective randomized clinical trial. Prostate Cancer Prostatic Dis 2021; 24:750-757.
26. Xu H, Wang Q, Lin C, Yin Z, He X, Pan J, et al. Synergism between cryoablation and GM-CSF: Enhanced immune function of splenic dendritic cells in mice with glioma. Neuroreport 2015; 26:346-353.
27. Yin Z, Lu G, Xiao Z, Liu T, He X, Wang Q, et al. Antitumor efficacy of argon-helium cryoablation-generated dendritic cell vaccine in glioma. Neuroreport 2014; 25:199-204.
28. Lin C, Wang Q, Lu G, Yin Z, He X, Xu H, et al. In-situ administration of dendritic cells following argon-helium cryosurgery enhances specific antiglioma immunity in mice. Neuroreport 2014; 25:900-908.
29. Bhat AA, Nisar S, Singh M, Ashraf B, Masoodi T, Prasad CP, et al. Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy. Cancer Commun (Lond) 2022; 42:689-715.
30. Ni L, Lu J. Interferon gamma in cancer immunotherapy. Cancer Med 2018; 7:4509-4516.
31. Yan WL, Shen KY, Tien CY, Chen YA, Liu SJ. Recent progress in GM-CSF-based cancer immunotherapy. Immunotherapy 2017; 9:347-360.
32. Kumar A, Taghi Khani A, Sanchez Ortiz A, Swaminathan S. GM-CSF: A double-edged sword in cancer immunotherapy. Front Immunol 2022; 13:901277.
33. Aarts BM, Klompenhouwer EG, Rice SL, Imani F, Baetens T, Bex A, et al. Cryoablation and immunotherapy: An overview of evidence on its synergy. Insights Imaging 2019; 10:53-64.
34. Jansen MC, van Hillegersberg R, Schoots IG, Levi M, Beek JF, Crezee H, et al. Cryoablation induces greater inflammatory and coagulative responses than radiofrequency ablation or laser-induced thermotherapy in a rat liver model. Surgery 2010; 147:686-695.
35. Thakur A, Littrup P, Paul EN, Adam B, Heilbrun LK, Lum LG. Induction of specific cellular and humoral responses against renal cell carcinoma after combination therapy with cryoablation and granulocyte-macrophage colony stimulating factor: A pilot study. J Immunother 2011; 34:457-467.
Iranian Journal of Basic Medical Sciences
Volume 28, Issue 5
May 2025
Pages 584-591

Files

Share

How to cite

Statistics